Rogers Jane E, Ajani Jaffer A
Pharmacy Clinical Programs, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.
Fac Rev. 2023 Feb 21;12:2. doi: 10.12703/r/12-2. eCollection 2023.
Gastric adenocarcinomas are a significant cause of cancer and cancer death, globally. The curative approach for those with diagnosed localized disease is with surgical resection and an adjunctive approach of perioperative chemotherapy, postoperative adjuvant therapy, or postoperative chemoradiation. Unfortunately, a universal standard approach is lacking for adjunctive therapy which in part has limited the progress achieved in this area. Metastatic disease is common in the Western world at diagnosis. Metastatic disease is treated palliatively with systemic therapy. Targeted therapy has stalled in approvals in gastric adenocarcinomas. Recently, we have seen the exploration of promising targets along with the addition of immune checkpoint inhibitors in select patients. Here, we review recent advances seen in gastric adenocarcinomas.
在全球范围内，胃腺癌是癌症及癌症死亡的一个重要原因。对于那些被诊断为局限性疾病的患者，治疗方法是手术切除以及围手术期化疗、术后辅助治疗或术后放化疗等辅助方法。不幸的是，辅助治疗缺乏通用的标准方法，这在一定程度上限制了该领域所取得的进展。在西方世界，转移性疾病在诊断时很常见。转移性疾病采用全身治疗进行姑息治疗。靶向治疗在胃腺癌的批准方面已陷入停滞。最近，我们看到了对有前景靶点的探索，以及在部分患者中加入免疫检查点抑制剂的情况。在此，我们综述胃腺癌的近期进展。
